45 minutes
Biopharma companies are using unique approaches to treating rare disease, realizing that each case is different from another. Hear how researchers and providers are not only tailoring a therapy for a specific patient but also the entire patient experience, and how this outlook has shaped their careers.

Speakers

Annemarie Crivelli - Chief Experience Officer
George Mulligan - SVP, Translational Medicine Mitobridge, An Astellas Co.
Kate Haviland - CEO, Blueprint Medicines
Paula Ragan - CEO, X4 Pharmaceuticals
Robert Gould - President and CEO, Fulcrum Therapeutics